Copper

Copper is essential trace element. Copper is used as a supplement in parenteral nutrition as a source of it in the prophylaxis and in the treatment of its deficiency states..

Copper is primarily indicated in conditions like Acute leukemia, Anaemia, Lymphomas, Neutropenia.

Copper is contraindicated in conditions like Hypersensitivity to the drug.

The severe or irreversible adverse effects of Copper, which give rise to further complications include Allergy, Hepatotoxicity, Hemolysis. The signs and symptoms that are produced after the acute overdosage of Copper include Diarrhea, Hypotonia, Photophobia, Prostration, Behavioral changes, Peripheral edema. The symptomatic adverse reactions produced by Copper are more or less tolerable and if they become severe, they can be treated symptomatically, these include Hot flushes, Shortening of breath.

Disease-related concerns: • Gastrointestinal fistulae: Patients with high output intestinal fistulae may require a larger dose than the recommended daily allowance (ASPEN, 2002). • Hepatic impairment: Use with caution in patients with hepatic impairment (eg, impaired biliary excretion or cholestatic liver disease). • Wilson's disease: Administration not recommended. Concurrent drug therapy issues: • TPN preparation: Copper ion may degrade ascorbic acid in TPN solutions. To avoid loss, add multivitamin additives to TPN solutions immediately prior to infusion or add to separate TPN solution container. Dosage form specific issues: • Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of >4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register, 2002). See manufacturer's labeling.

Disease-related concerns: • Gastrointestinal fistulae: Patients with high output intestinal fistulae may require a larger dose than the recommended daily allowance (ASPEN, 2002). • Hepatic impairment: Use with caution in patients with hepatic impairment (eg, impaired biliary excretion or cholestatic liver disease). • Wilson's disease: Administration not recommended. Concurrent drug therapy issues: • TPN preparation: Copper ion may degrade ascorbic acid in TPN solutions. To avoid loss, add multivitamin additives to TPN solutions immediately prior to infusion or add to separate TPN solution container. Dosage form specific issues: • Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of >4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register, 2002). See manufacturer's labeling.

0.5 to 1.5 mg (1 (1)) As recommended. PO — As required Scraped Dose — Excipient information presented when available (limited, particularly for generics); consult specific product labeling. Capsule, Oral [preservative free]: Cu-5: 5 mg [dye free] Solution, Intravenous: Generic: 0.4 mg/mL (10 mL) Tablet, Oral: Coppermin: 5 mg [corn free, rye free, wheat free]

No child dosage information is recorded for this medicine yet.

No neonatal dosage information is recorded for this medicine yet.

Ascorbic Acid: Copper may decrease the serum concentration of Ascorbic Acid. Management: To minimize the risk for ascorbic acid degradation, add multivitamin product to TPN solution immediately prior to infusion or administer multivitamin and copper in separate containers. Consider therapy modification

Tab, Inj Store in a well closed container.